远大医药(00512.HK) 公布,集团联营Sirtex Medical Pty Ltd的SIR-Spheres®钇微球注射液“易甘泰®”在美国开展的用于治疗不可切除肝细胞癌临床研究成功达到临床终点,标志着该项临床研究圆满完成。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-04-13 16:25。)AASTOCKS新闻
Source Link远大医药(00512.HK) 公布,集团联营Sirtex Medical Pty Ltd的SIR-Spheres®钇微球注射液“易甘泰®”在美国开展的用于治疗不可切除肝细胞癌临床研究成功达到临床终点,标志着该项临床研究圆满完成。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-04-13 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.